Results · Apr-Jun 2026 · filed 5 Sep 2026
Molbio Diagnostics Q1 FY27 results
Sales grew 310% to ₹408 crore from ₹99.7 crore in Apr-Jun 2025.
Operating profit was ₹101 crore, an operating margin of 24.6%.
Net profit turned positive: ₹52.7 crore against a loss of ₹23.9 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −27%, net profit −45%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 408.4 | 99.7 | +310% |
| Operating profit (EBITDA) | 100.6 | - | - |
| Operating margin | 24.6% | - | - |
| Net profit | 52.7 | -23.9 | turns positive |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 3 quarters
Filings that week
- 12 Sep 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 9 Sep 2026Change Of Corporate Identification Number (CIN) Of The Company.
- 8 Sep 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 8 Sep 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 7 Sep 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 7 Sep 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 5 Sep 2026Board Meeting Outcome for Outcome Of Board Meeting.
- 5 Sep 2026Outcome Of Board Meeting Held On Saturday, September 05, 2026
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.